Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

July 27, 2023

Study Completion Date

February 9, 2024

Conditions
Allergic Bronchopulmonary Aspergillosis
Interventions
DRUG

dupilumab

Single-use prefilled glass syringe administered by subcutaneous (SC) injection.

DRUG

Placebo

Matching placebo

Trial Locations (50)

1083

Regeneron Study Site, Budapest

1142

Regeneron Study Site, Sofia

4357

Regeneron Study Site, Leipzig

4700

Regeneron Study Site, Smolyan

5623

Regeneron Study Site, Eindhoven

6305

Regeneron Study Site, Haskovo

6815

Regeneron Study Site, Arnhem

7200

Regeneron Study Site, Razgrad

7207

Regeneron Study Site, Zutphen

10032

Regeneron Study Site, New York

10461

Regeneron Study Site, The Bronx

10717

Regeneron Study Site, Berlin

13015

Regeneron Study Site, Marseille

15801

Regeneron Study Site, DuBois

19140

Regeneron Study Site, Philadelphia

29609

Regeneron Study Site, Brest

34295

Regeneron Study Site, Montpellier

35033

Regeneron Study Site, Rennes

35209

Regeneron Study Site, Birmingham

37044

Regeneron Study Site, Tours

43235

Regeneron Study Site, Columbus

52242

Regeneron Study Site, Iowa City

60389

Regeneron Study Site, Frankfurt am Main

69004

Regeneron Study Site, Lyon

75018

Regeneron Study Site, Paris

80402

Regeneron Study Site, Gdansk

83706

Regeneron Study Site, Boise

85251

Regeneron Study Site, Scottsdale

90025

Regeneron Study Site, Los Angeles

92093

Regeneron Study Site, La Jolla

92506

Regeneron Study Site, Riverside

93301

Regeneron Study Site, Bakersfield

410169

Regeneron Study Site, Oradea

500051

Regeneron Study Site, Brasov

3191113

Regeneron Study Site, Naka-gun

7200001

Regeneron Study Site, Fukuyama

8320059

Regeneron Study Site, Yanagawa

259-1193

Regeneron Study Site, Kanagawa

454-8509

Regeneron Study Site, Nagoya

591-8555

Regeneron Study Site, Sakai

231-8682

Regeneron Study Site, Yokohama

1105AZ

Regeneron Study Site, Amsterdam

4818 CK

Regeneron Study Site, Breda

15-044

Regeneron Study Site, Bialystok

LE39QP

Regeneron Study Site, Leicester

L7 8XP

Regeneron Study Site, Liverpool

E1 2EF

Regeneron Study Site, London

SW3 6NP

Regeneron Study Site, London

M23 9LT

Regeneron Study Site, Wythenshawe

BD96RJ

Regeneron Study Site, Bradford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT04442269 - Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED) | Biotech Hunter | Biotech Hunter